REG - Braveheart Inv Group - Investment update – Phasefocus Holdings Limited

Braveheart InvestmentAnnouncement

31/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230531:nRSe0789Ba&default-theme=true

RNS Number : 0789B  Braveheart Investment Group plc  31 May 2023

31 May 2023

Braveheart Investment Group plc

("Braveheart", the "Company" or the "Group")

 

Investment update - Phasefocus Holdings Limited

 

Braveheart Investment Group (AIM: BRH), announces an update on Phasefocus
Holdings Limited ("Phasefocus"), a company within Braveheart's investment
portfolio and in which the Company has a 44.2% holding.

 

Phasefocus' imaging and analysis system, Livecyte®, uses a novel method for
high fidelity quantitative imaging and microscopy; this is known in the
scientific literature as "ptychography".

 

Phasefocus recently appointed Nexus Scientific, a specialist in cell analysis
instrument sales, to represent Livecyte® products in North America. Over the
coming months, Nexus will be running a series of customer workshops,
conference attendances and seminars, with the object of raising the profile
and sales of Livecyte® in the USA.

 

Dr. Peter Djali has been appointed as Phasefocus's Head of European Business
Development.  Peter has previously held senior commercial roles in a range of
biotech instrumentation companies, including Lumicks, CytoSMART, Isoplexis and
Essen Bioscience.  He brings with him a wealth of market sector experience
and relevant potential customer connections.  Peter will be building
Phasefocus's sales channel network within Europe.

 

In April and May, Martin Humphry, CEO of Phasefocus, visited its distributors
in Japan, China and the USA to raise the profile of Phasefocus and meet many
potential customers.

 

Two new Livecyte® applications have been developed and are scheduled for
launch before the end of 2023. These will be marketed as proprietary assays,
to meet the needs of cell biologists testing drug performance in
immuno-oncology and neurosciense applications. Livecyte® users have the
ability to continuously track thousands of individual cells and sustain cell
health and viability over prolonged durations. This fundamental feature
facilitates longitudinal studies involving live cells, thereby permitting a
more thorough exploration of dynamic cellular processes and the efficacy of
drugs on them.

 

Trevor Brown, Chief Executive Officer of Braveheart, commented:

 

"Phasefocus has gained momentum in a number of areas recently which your Board
is hopeful will lead to increased sales over the coming months."

 

For further information:

 Braveheart Investment Group plc                                Tel: 01738 587555
 Trevor Brown, Chief Executive Officer

 Viv Hallam, Executive Director

 Allenby Capital Limited (Nominated Adviser and Joint Broker)   Tel: 020 3328 5656
 James Reeve / George Payne

 Peterhouse Capital Limited (Joint Broker)                      Tel: 020 7469 0936
 Duncan Vasey / Lucy Williams

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDZGFKVGZGFZM